IP Library › Granted Patent US 12,274,714
Granted Patent B2
US 12,274,714 · App. 17/567,923 · Granted Apr 15, 2025

Early apoptotic cells for use treating sepsis

Inventors: Shai Novik (Ramat Hasharon, IL); Dror Mevorach (Jerusalem, IL)
Assignee: ENLIVEX THERAPEUTICS R&D LTD
A61K35/12A61K39/4611A61K39/4631A61K39/464412A61K39/464419A61P31/04A61K9/0019A61K2239/31A61K2239/38A61K2239/48A61K2239/59
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,714
App. No.
17/567,923
Granted
Apr 15, 2025
Kind
B2
Abstract

Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents.

Claims (18)

1. A method of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating sepsis, or any combination thereof, in a subject in need, comprising the step of administering a composition comprising a dose of early apoptotic cell population comprising 40-240×10{circumflex over ( )}6 cells/kg to said subject, wherein said early apoptotic cells comprise peripheral blood mononuclear cells having ≥40% AnnexinV+ and ≤15% propidium iodide+, and wherein said administering treats, prevents, inhibits, reduces the incidence of, ameliorates, or alleviates sepsis in said subject.

2. The method of claim 1 , wherein said dose comprises 140×10 6 cells/kg.

3. The method of claim 1 , wherein sepsis comprises mild or severe sepsis.

4. The method of claim 1 , wherein said treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating increases the survival of said subject.

5. The method of claim 1 , wherein said treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating reduces the incidence of organ failure or organ dysfunction, or organ damage, or a combination thereof.

6. The method of claim 5 , wherein organ failure comprises acute multiple organ failure.

7. The method of claim 1 , wherein said early apoptotic cell population comprises decreased non-quiescent non-apoptotic cells, a suppressed cellular activation of any living non-apoptotic cells, or a reduced proliferation of any living non-apoptotic cells, or any combination thereof.

8. The method of claim 1 , wherein said early apoptotic cell population comprises a pooled population of early apoptotic cells.

9. The method of claim 1 , wherein said subject is a human subject.

10. The method of claim 1 , wherein said administering comprises a single infusion of said early apoptotic cell population.

11. The method of claim 1 , wherein said administering comprises multiple infusions of said apoptotic cell population.

12. The method of claim 1 , wherein said administering comprises intra venal administration.

13. The method of claim 1 , further comprising administering an additional therapy.

14. The method of claim 13 , wherein said additional therapy comprises administering an antibiotic.

15. The method of claim 14 , wherein said antibiotic comprises ertapenem.

16. The method of claim 13 , wherein said additional therapy is administered prior to, concurrent with, or following administration of said early apoptotic cells.

17. The method of claim 1 , wherein said method comprises a first-line therapy.

18. The method of claim 1 , wherein said method comprises an adjuvant therapy.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2022
From: NOVIK, SHAI; MEVORACH, DROR
To: ENLIVEX THERAPEUTICS R&D LTD
Reel/Frame 061098/0840 →
CHANGE OF NAME Recorded Aug 1, 2022
From: ENLIVEX THERAPEUTICS LTD
To: ENLIVEX THERAPEUTICS R&D LTD
Reel/Frame 061033/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2022
From: LENTZ, JOSHUA
To: GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE GOVERNMENT OF THE UNITED STATES
Reel/Frame 060323/0480 →
Continuity (14)
Continuation 16194417 · Nov 19, 2018
Continuation In Part 15685086 · Aug 24, 2017
Continuation In Part 15551284
Continuation In Part PCTIL2017050196 · Feb 15, 2017
Continuation In Part PCTIL2016050430 · Apr 21, 2016
Provisional Application 62117752 · Feb 18, 2015
Provisional Application 62127218 · Mar 2, 2015
Provisional Application 62148227 · Apr 16, 2015
Provisional Application 62159365 · May 11, 2015
Provisional Application 62296622 · Feb 18, 2016
Provisional Application 62370741 · Aug 4, 2016
Provisional Application 62150305 · Apr 21, 2015
Provisional Application 62516714 · Jun 8, 2017
Related Publication 20220133799A1 · May 5, 2022
References Cited (400)
US 4036945A · Haber · 1977 [cited by applicant]
US 4331647A · Goldenberg · 1982 [cited by applicant]
US 4752614A · Albeck et al. · 1988 [cited by applicant]
US 4761490A · Albeck et al. · 1988 [cited by applicant]
US 4764461A · Albeck et al. · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4929739A · Sredni et al. · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 4956778A · Naito · 1990 [cited by applicant]
US 4962207A · Albeck et al. · 1990 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5093135A · Albeck et al. · 1992 [cited by applicant]
US 5102908A · Albeck et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5213899A · Lucas · 1993 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5906936A · Eshhar et al. · 1999 [cited by applicant]
US 5912172A · Eshhar et al. · 1999 [cited by applicant]
US 6489311B1 · Kennedy · 2002 [cited by applicant]
US 7056660B1 · Giesing et al. · 2006 [cited by applicant]
US 7521197B2 · Savage et al. · 2009 [cited by applicant]
US 7652065B2 · Albeck et al. · 2010 [cited by applicant]
US 7771715B2 · Schlom et al. · 2010 [cited by applicant]
US 7772373B2 · Hansen et al. · 2010 [cited by applicant]
US 7931903B2 · Hansen et al. · 2011 [cited by applicant]
US 8119101B2 · Byrd et al. · 2012 [cited by applicant]
US 8147800B2 · Mcbride et al. · 2012 [cited by applicant]
US 8211422B2 · Eshhar et al. · 2012 [cited by applicant]
US 8268317B2 · Govindan et al. · 2012 [cited by applicant]
US 8481003B2 · Griffiths et al. · 2013 [cited by applicant]
US 8506954B2 · Strober et al. · 2013 [cited by applicant]
US 8834886B2 · Govindan et al. · 2014 [cited by applicant]
US 8846026B2 · Plebanski et al. · 2014 [cited by applicant]
US 8889616B2 · Peterson et al. · 2014 [cited by applicant]
US 10077426B2 · Mevorach et al. · 2018 [cited by applicant]
US 10857181B2 · Mevorach et al. · 2020 [cited by applicant]
US 10927343B2 · Mevorach et al. · 2021 [cited by applicant]
US 11304976B2 · Novik · 2022 [cited by examiner]
US 11318163B2 · Novik · 2022 [cited by examiner]
US 11497767B2 · Novik · 2022 [cited by examiner]
US 11512289B2 · Novik · 2022 [cited by examiner]
US 11596652B2 · Novik · 2023 [cited by examiner]
US 20010033839A1 · Barbera-Guillem · 2001 [cited by applicant]
US 20020044924A1 · Bolton et al. · 2002 [cited by applicant]
US 20020137697A1 · Eshhar et al. · 2002 [cited by applicant]
US 20020193569A1 · Hanna · 2002 [cited by applicant]
US 20030036505A1 · Barash et al. · 2003 [cited by applicant]
US 20030207287A1 · Short · 2003 [cited by applicant]
US 20040009939A1 · Chada et al. · 2004 [cited by applicant]
US 20040018557A1 · Qu et al. · 2004 [cited by applicant]
US 20040019195A1 · Scholm et al. · 2004 [cited by applicant]
US 20040053348A1 · Faris et al. · 2004 [cited by applicant]
US 20040072288A1 · Collas et al. · 2004 [cited by applicant]
US 20040083497A1 · Raitano et al. · 2004 [cited by applicant]
US 20040115193A1 · Hansen et al. · 2004 [cited by applicant]
US 20040192597A1 · Raitano et al. · 2004 [cited by applicant]
US 20040202666A1 · Griffiths · 2004 [cited by applicant]
US 20040213778A1 · Challita-Eid et al. · 2004 [cited by applicant]
US 20040214212A1 · Raitano et al. · 2004 [cited by applicant]
US 20040214783A1 · Terman et al. · 2004 [cited by applicant]
US 20040219156A1 · Goldenberg et al. · 2004 [cited by applicant]
US 20040253245A1 · Briend et al. · 2004 [cited by applicant]
US 20050079184A1 · Hsing-Chang et al. · 2005 [cited by applicant]
US 20050084913A1 · Punnonen et al. · 2005 [cited by applicant]
US 20050113297A1 · Francois et al. · 2005 [cited by applicant]
US 20050136435A1 · Kanner et al. · 2005 [cited by applicant]
US 20050191311A1 · Raitano et al. · 2005 [cited by applicant]
US 20050191312A1 · Raitano et al. · 2005 [cited by applicant]
US 20050191313A1 · Barbera-Guillem · 2005 [cited by applicant]
US 20050196754A1 · Drmanac et al. · 2005 [cited by applicant]
US 20050202098A1 · Mevorach · 2005 [cited by applicant]
US 20050276822A1 · Wiseman et al. · 2005 [cited by applicant]
US 20060029940A1 · Ge et al. · 2006 [cited by applicant]
US 20060052295A1 · Terman · 2006 [cited by applicant]
US 20060140936A1 · Goldenberg et al. · 2006 [cited by applicant]
US 20060193865A1 · Govindan et al. · 2006 [cited by applicant]
US 20060228357A1 · Chang et al. · 2006 [cited by applicant]
US 20070059729A1 · Faris et al. · 2007 [cited by applicant]
US 20070086942A1 · Chang et al. · 2007 [cited by applicant]
US 20070298051A1 · Barouch et al. · 2007 [cited by applicant]
US 20080004287A1 · Ma et al. · 2008 [cited by applicant]
US 20080081791A1 · Huang et al. · 2008 [cited by applicant]
US 20080108794A1 · Goldenberg · 2008 [cited by applicant]
US 20080138333A1 · Hansen et al. · 2008 [cited by applicant]
US 20080159993A1 · Stauss · 2008 [cited by applicant]
US 20080166342A1 · Hansen · 2008 [cited by applicant]
US 20080166363A1 · Govindan et al. · 2008 [cited by applicant]
US 20080181885A1 · Raitano et al. · 2008 [cited by applicant]
US 20080241141A1 · Goldenberg · 2008 [cited by applicant]
US 20080241145A1 · Goldenberg · 2008 [cited by applicant]
US 20090041804A1 · Schlom et al. · 2009 [cited by applicant]
US 20090123467A1 · Bedi et al. · 2009 [cited by applicant]
US 20090155166A1 · Mcbride et al. · 2009 [cited by applicant]
US 20090162315A1 · Terman et al. · 2009 [cited by applicant]
US 20090192114A1 · Ovcharenko et al. · 2009 [cited by applicant]
US 20090214550A1 · Sahin et al. · 2009 [cited by applicant]
US 20090215895A1 · Ferrante et al. · 2009 [cited by applicant]
US 20090298195A1 · Ruker et al. · 2009 [cited by applicant]
US 20100015046A1 · Govindan et al. · 2010 [cited by applicant]
US 20100040589A1 · Spetz-Holmgren et al. · 2010 [cited by applicant]
US 20100104589A1 · Govindan et al. · 2010 [cited by applicant]
US 20100119511A1 · Wang et al. · 2010 [cited by applicant]
US 20100135974A1 · Eshhar et al. · 2010 [cited by applicant]
US 20100233251A1 · Von et al. · 2010 [cited by applicant]
US 20100266496A1 · Hansen et al. · 2010 [cited by applicant]
US 20100266497A1 · Hansen et al. · 2010 [cited by applicant]
US 20100272636A1 · Byrd et al. · 2010 [cited by applicant]
US 20110008393A1 · Kanner et al. · 2011 [cited by applicant]
US 20110027295A1 · Powell et al. · 2011 [cited by applicant]
US 20110038869A1 · Van Den et al. · 2011 [cited by applicant]
US 20110183870A1 · Pan et al. · 2011 [cited by applicant]
US 20110280801A1 · Mcbride et al. · 2011 [cited by applicant]
US 20110293513A1 · Govindan et al. · 2011 [cited by applicant]
US 20110300156A1 · Verploegen et al. · 2011 [cited by applicant]
US 20110311450A1 · Levine et al. · 2011 [cited by applicant]
US 20120082725A1 · Plebanski · 2012 [cited by applicant]
US 20120093842A1 · Eshhar et al. · 2012 [cited by applicant]
US 20120196762A1 · Paradis et al. · 2012 [cited by applicant]
US 20120201746A1 · Liu et al. · 2012 [cited by applicant]
US 20120219617A1 · Peterson et al. · 2012 [cited by applicant]
US 20120328564A1 · Govindan et al. · 2012 [cited by applicant]
US 20130039911A1 · Bedi et al. · 2013 [cited by applicant]
US 20130045191A1 · Weinschenk et al. · 2013 [cited by applicant]
US 20130095034A1 · Griffiths et al. · 2013 [cited by applicant]
US 20130101590A1 · Arnett et al. · 2013 [cited by applicant]
US 20130136718A1 · Chien et al. · 2013 [cited by applicant]
US 20130156794A1 · Eshhar et al. · 2013 [cited by applicant]
US 20130171064A1 · Hans et al. · 2013 [cited by applicant]
US 20130177498A1 · Goldenberg et al. · 2013 [cited by applicant]
US 20130259891A1 · Harn et al. · 2013 [cited by applicant]
US 20130280220A1 · Ahmed et al. · 2013 [cited by applicant]
US 20130287857A1 · Von et al. · 2013 [cited by applicant]
US 20140030273A1 · Verploegen et al. · 2014 [cited by applicant]
US 20140050660A1 · Chang et al. · 2014 [cited by applicant]
US 20140050709A1 · Leen et al. · 2014 [cited by applicant]
US 20140099254A1 · Chang et al. · 2014 [cited by applicant]
US 20140099258A1 · Govindan et al. · 2014 [cited by applicant]
US 20140099309A1 · Powell et al. · 2014 [cited by applicant]
US 20140134265A1 · Buggy et al. · 2014 [cited by applicant]
US 20140271582A1 · Forman et al. · 2014 [cited by applicant]
US 20140294765A1 · Cojocaru et al. · 2014 [cited by applicant]
US 20140336105A1 · Shai et al. · 2014 [cited by applicant]
US 20140341917A1 · Nastri et al. · 2014 [cited by applicant]
US 20150023937A1 · Vera et al. · 2015 [cited by applicant]
US 20150025812A1 · Paradis et al. · 2015 [cited by applicant]
US 20150275175A1 · Mevorach et al. · 2015 [cited by applicant]
US 20160017048A1 · Dotti et al. · 2016 [cited by applicant]
US 20170360836A1 · Novik et al. · 2017 [cited by applicant]
US 20180094244A1 · Novik et al. · 2018 [cited by applicant]
US 20180104277A1 · Mevorach et al. · 2018 [cited by applicant]
US 20190083535A1 · Novik et al. · 2019 [cited by applicant]
US 20190175649A1 · Novik et al. · 2019 [cited by applicant]
US 20200009191A1 · Novik et al. · 2020 [cited by applicant]
US 20200009192A1 · Novik et al. · 2020 [cited by applicant]
US 20200061116A1 · Novik et al. · 2020 [cited by applicant]
US 20200121718A1 · Novik et al. · 2020 [cited by applicant]
US 20200289557A1 · Novik et al. · 2020 [cited by applicant]
US 20210038644A1 · Mevorach et al. · 2021 [cited by applicant]
US 20210228633A1 · Novik et al. · 2021 [cited by applicant]
CN 101121018A · 2008 [cited by applicant]
CN 102908352A · 2013 [cited by applicant]
WO WO1993019163A1 · 1993 [cited by applicant]
WO WO1997015669A1 · 1997 [cited by applicant]
WO WO2000031239A1 · 2000 [cited by applicant]
WO WO2001089536A2 · 2001 [cited by applicant]
WO WO2001089537A2 · 2001 [cited by applicant]
WO WO2001097844A1 · 2001 [cited by applicant]
WO WO2002082041A2 · 2002 [cited by applicant]
WO WO2003029293A2 · 2003 [cited by applicant]
WO WO2003033654A2 · 2003 [cited by applicant]
WO WO2003074567A2 · 2003 [cited by applicant]
WO WO2003074569A2 · 2003 [cited by applicant]
WO WO2004016734A2 · 2004 [cited by applicant]
WO WO2004016736A2 · 2004 [cited by applicant]
WO WO2004016762A2 · 2004 [cited by applicant]
WO WO2004016799A2 · 2004 [cited by applicant]
WO WO2004039412A2 · 2004 [cited by applicant]
WO WO2004058298A1 · 2004 [cited by applicant]
WO WO2004067038A1 · 2004 [cited by applicant]
WO WO2004067716A2 · 2004 [cited by applicant]
WO WO2004076644A2 · 2004 [cited by applicant]
WO WO2004093808A2 · 2004 [cited by applicant]
WO WO2004098515A2 · 2004 [cited by applicant]
WO WO2004108753A1 · 2004 [cited by applicant]
WO WO2005014618A2 · 2005 [cited by applicant]
WO WO2005014780A2 · 2005 [cited by applicant]
WO WO2005019429A2 · 2005 [cited by applicant]
WO WO2005049852A2 · 2005 [cited by applicant]
WO WO2005052119A2 · 2005 [cited by applicant]
WO WO2005073164A1 · 2005 [cited by applicant]
WO WO2005117846A2 · 2005 [cited by applicant]
WO WO2005123908A2 · 2005 [cited by applicant]
WO WO2006000787A2 · 2006 [cited by applicant]
WO WO2006004620A2 · 2006 [cited by applicant]
WO WO2006022722A1 · 2006 [cited by applicant]
WO WO2006055004A1 · 2006 [cited by applicant]
WO WO2006063150A2 · 2006 [cited by applicant]
WO WO2006072620A1 · 2006 [cited by applicant]
WO WO2006117786A1 · 2006 [cited by applicant]
WO WO2006120439A2 · 2006 [cited by applicant]
WO WO2006107617A2 · 2006 [cited by applicant]
WO WO2006135454A1 · 2006 [cited by applicant]
WO WO2007046893A2 · 2007 [cited by applicant]
WO WO2008005268A1 · 2008 [cited by applicant]
WO WO2008056174A2 · 2008 [cited by applicant]
WO WO2008095141A2 · 2008 [cited by applicant]
WO WO2008137901A2 · 2008 [cited by applicant]
WO WO2010070105A1 · 2010 [cited by applicant]
WO WO2011088226A2 · 2011 [cited by applicant]
WO WO2011109440A1 · 2011 [cited by applicant]
WO WO2011109789A2 · 2011 [cited by applicant]
WO WO2011110642A2 · 2011 [cited by applicant]
WO WO2011139629A2 · 2011 [cited by applicant]
WO WO2011140170A1 · 2011 [cited by applicant]
WO WO2011144358A1 · 2011 [cited by applicant]
WO WO2011147986A1 · 2011 [cited by applicant]
WO WO2012024543A1 · 2012 [cited by applicant]
WO WO2012088302A2 · 2012 [cited by applicant]
WO WO2012104344A1 · 2012 [cited by applicant]
WO WO2012115885A1 · 2012 [cited by applicant]
WO WO2012116225A2 · 2012 [cited by applicant]
WO WO2012138858A1 · 2012 [cited by applicant]
WO WO2012174282A2 · 2012 [cited by applicant]
WO WO2013022995A2 · 2013 [cited by applicant]
WO WO2013025972A1 · 2013 [cited by applicant]
WO WO2013079174A1 · 2013 [cited by applicant]
WO WO2013105089A2 · 2013 [cited by applicant]
WO WO2013112801A1 · 2013 [cited by applicant]
WO WO2013130683A2 · 2013 [cited by applicant]
WO WO2013136334A2 · 2013 [cited by applicant]
WO WO2013155375A1 · 2013 [cited by applicant]
WO WO2014011984A1 · 2014 [cited by applicant]
WO WO2014028560A2 · 2014 [cited by applicant]
WO WO2014055657A1 · 2014 [cited by applicant]
WO WO2014071231A1 · 2014 [cited by applicant]
WO WO2014071379A1 · 2014 [cited by applicant]
WO WO2014080251A1 · 2014 [cited by applicant]
WO WO2014082083A1 · 2014 [cited by applicant]
WO WO2014087408A1 · 2014 [cited by applicant]
WO WO2004061113A1 · 2014 [cited by applicant]
WO WO2014106666 · 2014 [cited by applicant]
WO WO2014068408A2 · 2014 [cited by applicant]
WO WO2014122467A1 · 2014 [cited by applicant]
WO WO2014138704A1 · 2014 [cited by applicant]
WO WO2014144622A2 · 2014 [cited by applicant]
WO WO2014145578A1 · 2014 [cited by applicant]
WO WO2014151085A1 · 2014 [cited by applicant]
WO WO2014153114A1 · 2014 [cited by applicant]
WO WO2014163684A1 · 2014 [cited by applicant]
WO WO2014164554A1 · 2014 [cited by applicant]
WO WO2014172584A1 · 2014 [cited by applicant]
WO WO2014186773A1 · 2014 [cited by applicant]
WO WO2014193999A2 · 2014 [cited by applicant]
WO WO2014197638A2 · 2014 [cited by applicant]
WO WO2014201021A2 · 2014 [cited by applicant]
WO WO2015010096A1 · 2015 [cited by applicant]
WO WO2015089495A2 · 2015 [cited by applicant]
WO WO2016132366A1 · 2016 [cited by applicant]
WO WO2016170541 · 2016 [cited by applicant]
WO WO2017141243 · 2017 [cited by applicant]
WO WO2019038758A1 · 2019 [cited by applicant]
Amarilyo et al. “iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-κB-dependent blockade.” European Journal of Immunology 40(3):699-709, 2010. [cited by applicant]
Angus et al. “Severe sepsis and septic shock” N Engl J Med. Aug. 29, 2013;369:840-51. [cited by applicant]
Aziz et al. “Current trends in inflammatory and immunomodulatory mediators in sepsis” Journal of leukocyte biology. Mar. 2013;93(3):329-42. [cited by applicant]
Barrett et al. “Treatment of advanced leukemia in mice with mRNA engineered T cells.” Human Gene Therapy 22(12) 1575-1586, 2011. [cited by applicant]
Barrett et al. “Chimeric antigen receptor therapy for cancer.” Annual Review of Medicine 65: 333-347, 2014. [cited by applicant]
Bird et al. “Single-chain antigen-binding proteins” Science. Oct. 21, 1988;242(4877):423-6. [cited by applicant]
Bittencourt et al. “Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers” Blood, 98(1), 224-230, 2001. [cited by applicant]
Bonnefoy et al. “Factors produced by macrophages eliminating apoptotic cells demonstrate pro-resolutive properties and terminate ongoing inflammation” Frontiers in Immunology. Nov. 13, 2018,9:2586. [cited by applicant]
Brentjens et al. “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.” Nature Medicine 9(3): 279, 2003. [cited by applicant]
Brentjens et al. “Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.” Clinical Cancer Research 13(18): 5426-5435, 2007. [cited by applicant]
Brentjens et al. “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.” Blood 118.18: 4817-4828, 2011. [cited by applicant]
Brentjens et al. “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.” Science Translational Medicine 5(177): 138-177, 2013. [cited by applicant]
Brigham et al. “Rapid communication: In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle.” The American Journal of The Medical Sciences 298(4): 278-281, 1989. [cited by applicant]
Brocks et al. “A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono-and bivalent scFv derivative in insect cells.” Immunotechnology 3(3):173-184, 1997. [cited by applicant]
Butterfield LH. “Cancer vaccines” BMJ 350, h988. British Medical Journal Publishing Group. 2015. [cited by applicant]
Canna et al. “Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes.” Pediatric Clinics 59(2): 329-344, 2012. [cited by applicant]
Cartellieri, M, “Chimeric antigen receptor-engineered T cells for immunotherapy of cancer”. Journal of Biomedicine and Biotechnology, Article ID 956304, doi:10.1155/2010/956304, 2010. [cited by applicant]
Champlin et al. “Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.” Blood 76(2): 418-423, 1990. [cited by applicant]
Chaudhry et al. “Role of cytokines as a double-edged sword in sepsis” In Vivo. Nov. 1, 2013;27(6):669-84. [cited by applicant]
Cheadle et al. “Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.” The Journal of Immunology 192(8): 3654-3665, 2014. [cited by applicant]
Chekmasova et al. “Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.” Clinical Cancer Research 16(14): 3… [cited by applicant]
Cheng et al. “NK cell-based immunotherapy for malignant diseases.” Cellular & Molecular Immunology 10(3): 230, 2013. [cited by applicant]
Chousterman et al. “Cytokine storm and sepsis disease pathogenesis” In Seminars in immunopathology Jul. 1, 2017 (vol. 39, No. 5, pp. 517-528). Springer Berlin Heidelberg. [cited by applicant]
Chousterman et al. “Is there a role for hematopoietic growth factors during sepsis?” Frontiers in immunology. Jun. 21, 2018;9:1015. [cited by applicant]
Clair et al. “The calm after the cytokine storm: lessons from the TGN1412 trial.” The Journal of clinical investigation 118(4): 1344-1347, 2008. [cited by applicant]
Cohen et al. “Sepsis studies need new direction” The Lancet infectious diseases. Jul. 1, 2012;12(7):503-5. [cited by applicant]
Cooke et al. “An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.” Blood 88(8): 3230-3239, 1996. [cited by applicant]
Curran et al. “Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.” The Journal of Gene Medicine 14(6): 405-415, 2012. [cited by applicant]
Davila et al. “How do CARs work? Early insights from recent clinical studies targeting CD19.” Oncoimmunology 1(9): 1577-1583, 2012. [cited by applicant]
Davila et al. “CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.” PLOS one 8(4): e61338, 2013. [cited by applicant]
Davila et al. “Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.” Science Translational Medicine 6(224): 224-225, 2014. [cited by applicant]
Essand et al. “Genetically engineered T cells for the treatment of cancer.” Journal of Internal Medicine 273(2): 166-181, 2013. [cited by applicant]
European Search report issued for European Application No. 17752797.5 dated Feb. 5, 2020. [cited by applicant]
European Search Report for European Application No. 21164060.2 dated Jul. 5, 2021. [cited by applicant]
Felgner et al. “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.” Proceedings of the National Academy of Sciences 84(21): 7413-7417, 1987. [cited by applicant]
Fife et al. “Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.” The Journal of Clinical Investigation 116(8): 2252-2261, 2006. [cited by applicant]
Finfer et al. “Adult-population Incidence of severe sepsis in Australian and New Zealand intensive care units” Intensive care medicine. Apr. 1, 2004;30(4):589-96. [cited by applicant]
Fishwild et al. “High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice” Nature biotechnology. Jul. 1996;14(7):845-51. [cited by applicant]
Fleischmann et al. “Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations” American journal of respiratory and critical care medicine. Feb. 1, 2016;193(3):259-72. [cited by applicant]
Gallardo et al. “Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.” Bone Mar… [cited by applicant]
Ganss et al. “Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.” Cancer Research 62: 1462-1470, (Mar. 2002). [cited by applicant]
Gauthier et al. “Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy” Current research in translational medicine. May 1, 2018;66(2):50-2. [cited by applicant]
Giavridis et al. “CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade” Nature medicine. Jun. 2018;24(6):731-8. [cited by applicant]
Giomarelli et al. “Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-1.” Thrombosis and Haemostasis 97(06): 955-963, 2007. [cited by applicant]
Goding, James W. Monoclonal antibodies: principles and practice. Elsevier, pp. 59-103, 1996. [cited by applicant]
Gong et al. “Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.” Neoplasia … [cited by applicant]
Grau et al. “Apoptotic cells induce NF-κB and inflammasome negative signaling.” PloS one 10(3): e0122440, 2015. [cited by applicant]
Griffith et al. “Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells” Immunity. Oct. 28, 2011;35(4):456-66. [cited by applicant]
Haji-Fatahaliha et al. “CAR-modified T-cell therapy for cancer: an updated review.” Artificial Cells, Nanomedicine, and Biotechnology 44(6): 1339-1349,2016. [cited by applicant]
Han et al. “Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.” Journal of Hematology & Oncology 69(47), 2013. [cited by applicant]
Henson et al. “Antiinflammatory effects of apoptotic cells” The Journal of clinical investigation. Jul. 1, 2013;123(7):2773-4. [cited by applicant]
Ho et al. “Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties.” Biochimica et Biophysica Acta (BBA)-Molecular Ba… [cited by applicant]
Hoffman et al. “Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.” Nature genetics 29.3: 301, 2001. [cited by applicant]
Hoogenboom et al. “By-passing immunisation: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro” Journal of molecular biology. Sep. 20, 1992;227(2):381-8. [cited by applicant]
Hotchkiss et al. “Sepsis and septic shock” Nature reviews Disease primers. Jun. 30, 2016;2(1):1-21. [cited by applicant]
Huang et al. “A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China” The Lancet Infectious Diseases. May 1, 2020;20(5):534-5. [cited by applicant]
Huston et al. “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Inbar et al. “Localization of antibody-combining sites within the variable portions of heavy and light chains” Proceedings of the National Academy of Sciences. Sep. 1, 1972;69(9):2659-62. [cited by applicant]
Inoue et al. “Dose dependent effect of anti-CTLA-4 on survival in sepsis” Shock (Augusta, Ga.). Jul. 2011;36(1):38. [cited by applicant]
International Search Report and Written opinion issued for International Application No. PCT/IL2016/050194 dated May 18, 2016. [cited by applicant]
International Search Report and Written opinion issued for International Application No. PCT/IL2017/050196 dated Jun. 11, 2017. [cited by applicant]
International Search Report and Written opinion issued for International Application No. PCT/IL2016/050430 dated Jul. 13, 2016. [cited by applicant]
International Search Report and Written opinion issued for International Application No. PCT/IL2019/051250 dated July Mar. 26, 2020. [cited by applicant]
International Search Report for PCT Application No. PCT/IL2020/051011 dated Mar. 4, 2021. [cited by applicant]
Jagasia et al. “National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report.” Biology of Blood… [cited by applicant]
Jensen et al. “Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.” Immunological Reviews 257(1): 127-144, 2014. [cited by applicant]
Jones et al. “Replacing the complementarity-determining regions in a human antibody with those from a mouse” Nature. May 1986;321(6069):522-5. [cited by applicant]
Jones et al. “Minireview: glucagon in stress and energy homeostasis” Endocrinology. Mar. 1, 2012;153(3):1049-54. [cited by applicant]
Kalechman et al. “Up-regulation by ammonium trichloro (dioxoethylene-0, 0′) tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101” The Journal of Immunology. Oc… [cited by applicant]
Kalinski, Pawel. “Regulation of immune responses by prostaglandin E2.” The Journal of Immunology 188(1): 21-28, 2012. [cited by applicant]
Karlsson et al. “Combining Car T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.” Cancer Gene Therapy 20(7): 386, 2013. [cited by applicant]
Kershaw et al. “Clinical application of genetically modified T cells in cancer therapy” Clinical & translational immunology. May 2014;3(5):e16. [cited by applicant]
Knaus et al. “Apache II: a severity of disease classification system” Critical care medicine. Oct. 1, 1985;13(10):818-29. [cited by applicant]
Kobayashi et al. “A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells.” Biochemical and Biophysical Research Communications 453(4): 798-803, 2014. [cited by applicant]
Kobayashi Y. “Inadequate Production of H2 by Gut Microbiota and Parkinson Disease” J. Leukoc. Biol.. 2010;88:1157-62. [cited by applicant]
Kochenderfer et al. “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.” Blood 119(12): 2709-2720, 2012. [cited by applicant]
Köhler et al. “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature 256 (5517): 495, 1975. [cited by applicant]
Krispin et al. “Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states” Blood 108: 3580-3589, 2006. [cited by applicant]
Larrick et al. “PCR amplification of antibody genes” Methods. Apr. 1, 1991;2(2):106-10. [cited by applicant]
Ledbetter et al. “Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5.” Critical Reviews in Immunology 17.5-6: 427-435, 1997. Abstract only. [cited by applicant]
Lee et al. “Current concepts in the diagnosis and management of cytokine release syndrome.” Blood 124, pp. 188-195, 2014. [cited by applicant]
Lee et al. “Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction” European Respiratory Journal. Aug. 1, 2012:40(2):424-35. [cited by applicant]
Levy et al. “The surviving sepsis campaign bundle: 2018 update” Intensive care medicine. Jun. 1, 2018;44(6):925-8. [cited by applicant]
Li et al. “Interleukin-10/lymphocyte ratio predicts mortality in severe septic patients” PloS one. Jun. 19, 2017;12(6):e0179050. [cited by applicant]
Libraty et al. “Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections” The Journal of infectious diseases. May 1, 2002;185(9):1213-21. [cited by applicant]
Liu et al. “Hospital deaths in patients with sepsis from 2 independent cohorts” Jama. Jul. 2, 2014;312(1):90-2. [cited by applicant]
Lonberg et al. “Antigen-specific human antibodies from mice comprising four distinct genetic modifications” Nature. Apr. 28, 1994;368(6474):856-9. [cited by applicant]
Lonberg et al. “Human antibodies from transgenic mice” International reviews of immunology. Jan. 1, 1995;13(1):65-93. [cited by applicant]
Machado et al. “The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study” The Lancet Infectious Diseases. Nov. 1, 2017;17(11):1180-9. [cited by applicant]
Magenau et al. “Next generation treatment of acute graft-versus-host disease.” Leukemia 28 (12): 2283, 2014. [cited by applicant]
Maldarelli, Frank, et al. “Specific HIV integration sites are linked to clonal expansion and persistence of infected cells.” Science vol. 345 Issue 6193: 179-183, 2014. [cited by applicant]
Malinin TI. “Injury of human polymorphonuclear granulocytes frozen in the presence of cryoprotective agents” Cryobiology. Apr. 1, 1972;9(2):123-30. [cited by applicant]
Marcondes et al. “α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.” Blood 124 (18): 2881-2891, 2014. [cited by applicant]
Marks et al. “By-passing immunization: human antibodies from V-gene libraries displayed on phage” Journal of molecular biology. Dec. 5, 1991;222(3):581-97. [cited by applicant]
Marks et al. “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling” Bio/technology. Jul. 1992;10(7):779-83. [cited by applicant]
Martínez et al. “Graft-versus-host disease therapy: something else beyond glucocorticoids?” Haematologica, Journal of The Ferrata Stori Foundation, vol. 96, Issue 9:1249-1251, 2011. [cited by applicant]
Martin-Loeches et al. “Management of severe sepsis: advances, challenges, and current status” Drug design, development and therapy. 2015;9:2079. [cited by applicant]
Maude et al. “Managing cytokine release syndrome associated with novel T cell-engaging therapies.” Cancer Journal (Sudbury, Mass.) 20 (2): 119, 2014. [cited by applicant]
McClain et al. “Clinical features and diagnosis of hemophagocytic lymphohistiocytosis.” UpToDate p. 1-22, 2016. https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis. [cited by applicant]
Mehta et al. “HLH Across Speciality Collaboration. COVID-19: consider cytokine storm syndromes and immunosuppression” Lancet (London, England). Mar. 28, 2020;395(10229):1033. [cited by applicant]
Mevorach et al. “Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.… [cited by applicant]
Mevorach et al. “Early Apoptotic Cells (ApoCell) as Prophylaxis of Graft-Versus-Host Disease Is Safe and Effective: 1 Year Follow-up and Mechanism of Action.” Biology of Blood and Marrow Transplantation 21 (2): S339-S34… [cited by applicant]
Mevorach et al., Apoptotic Cells for the Prevention of Cytokine Release Syndrome (CRS) in CAR T-Cell Therapy, Blood 128:1626, 2016. [cited by applicant]
Meyer et al. “Low trilodothyronine syndrome: a prognostic marker for outcome in sepsis?” Endocrine. Apr. 1, 2011;39(2):167-74. [cited by applicant]
Minne et al. “Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review” Critical care. Dec. 1, 2008;12(6):R161. [cited by applicant]
Mohebtash et al. “Therapeutic prostate cancer vaccines: a review of the latest developments” Current opinion in investigational drugs (London, England: 2000). Dec. 2008;9(12):1296. [cited by applicant]
Moon et al. “Use of APACHE II and SAPS II to predict mortality for hemorrhagic and ischemic stroke patients” Journal of Clinical Neuroscience. Jan. 1, 2015;22(1):111-5. [cited by applicant]
Moosmayer et al. “A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity.” Therapeutic Immunology 2 (1): 31-40, 1995. [cited by applicant]
Morelli et al. “Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells” Apoptosis. Sep. 2010;15(9):1083-97. [cited by applicant]
Morrison SL. “Success in specification” Nature. Apr. 1994;368(6474):812-3. [cited by applicant]
Munson et al. “Ligand: A versatile computerized approach for characterization of ligand-binding systems”, Analytical Biochemistry, vol. 107, Issue1 pp. 220-239, Sep. 1980. [cited by applicant]
Murthy et al. “Cytokine release syndrome: current perspectives” ImmunoTargets and therapy. 2019;8:43. [cited by applicant]
Nelson J. Lee. “The Otherness of Self: Microchimerism in Heath and Disease”, Trends in Immunology, vol. 33, Issue 8, pp. 421-427, Aug. 2012. [cited by applicant]
Neuberger M. “Generating high-avidity human Mabs in mice” Nature biotechnology. Jul. 1996; 14(7):826. [cited by applicant]
Neven et al. “Cryopyrinopathies: update on pathogenesis and treatment.” Nature Reviews Rheumatology 4 (9): 481, 2008. [cited by applicant]
Ono et al. “Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells.” Neuroscience Letters 117 (3): 259-263, 1990. [cited by applicant]
Pack et al. “Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of [cited by applicant]
Peter et al. “scFv single chain antibody variable fragment as inverse agonist of the β2-adrenergic receptor.” Journal of Biological Chemistry 278 (38): 36740-36747, 2003. [cited by applicant]
Peter et al. “Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopo lysaccharide-induced cachexia in rats.” Journal of Cachexia, Sarcopenia and Muscle 4(1): 79-88, 2013. [cited by applicant]
Plikat et al. “Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit” Metabolism. Feb. 1, 2007;56(2):239-44. [cited by applicant]
Poon et al. “Apoptotic cell clearance: basic biology and therapeutic potential.” Nature Reviews Immunology 14(3): 166, 2014. [cited by applicant]
Porter RR. “The hydrolysis of rabbit y-globulin and antibodies with crystalline papain” Biochemical Journal. Sep. 1, 1959,73(1):119-27. [cited by applicant]
Presta LG. “Antibody engineering” Current Opinion in Structural Biology. Aug. 1, 1992;2(4):593-6. [cited by applicant]
Pugin et al. “Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1” American journal of respiratory and critical care medicine. Jun. 1996;153(6):1850-6. [cited by applicant]
Pupjalis et al. “Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signaling.” EMBO Molecular Medicine 3(2): 102-114, 2011. [cited by applicant]
Raith et al. “Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit” Jama. Jan. 17, 2017;317(3):290-300. [cited by applicant]
Reinhart et al. “Recognizing sepsis as a global health priority—a WHO resolution” New England Journal of Medicine. Aug. 3, 2017;377(5):414-7. [cited by applicant]
Rello et al. “Sepsis: a review of advances in management” Advances in Therapy. Nov. 1, 2017;34(11):2393-411. [cited by applicant]
Ren Y. et al., “Apoptotic Cells Protect Mice against Lipopolysaccharide-Induced Shock”, The Journal of Immunology, J Immunol Apr. 1, 180 (7) 4978-4985, 2008. [cited by applicant]
Rhee et al. “Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014” Jama. Oct. 3, 2017;318(13):1241-9. [cited by applicant]
Rhodes et al. “Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016” Intensive care medicine. Mar. 1, 2017;43(3):304-77. [cited by applicant]
Riechmann et al. “Reshaping human antibodies for therapy” Nature. Mar. 1988;332(6162):323-7. [cited by applicant]
Rowan et al. “Intensive Care Society's Apache II study in Britain and Ireland—I: Variations in case mix of adult admissions to general intensive care units and impact on outcome” British Medical Journal. Oct. 16, 1993;3… [cited by applicant]
Rowlings et al. “IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade” British journal of haematology. Jun. 1997;97(4):855-64. [cited by applicant]